Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. More Details
No risks detected for REGN from our risk checks.
Outstanding track record with excellent balance sheet.
Share Price & News
How has Regeneron Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: REGN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: REGN's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: REGN underperformed the US Biotechs industry which returned 31.3% over the past year.
Return vs Market: REGN underperformed the US Market which returned 55.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Regeneron Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWe Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease
3 weeks ago | Simply Wall StInvestors Who Bought Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Three Years Ago Are Now Up 48%
1 month ago | Simply Wall StHow Much Are Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Taking Off The Table?
Is Regeneron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: REGN ($475.17) is trading below our estimate of fair value ($667.27)
Significantly Below Fair Value: REGN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: REGN is good value based on its PE Ratio (14.6x) compared to the US Biotechs industry average (29.9x).
PE vs Market: REGN is good value based on its PE Ratio (14.6x) compared to the US market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: REGN is poor value based on its PEG Ratio (4.3x)
Price to Book Ratio
PB vs Industry: REGN is overvalued based on its PB Ratio (4.5x) compared to the US Biotechs industry average (3.9x).
How is Regeneron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: REGN's forecast earnings growth (3.4% per year) is above the savings rate (2%).
Earnings vs Market: REGN's earnings (3.4% per year) are forecast to grow slower than the US market (18.7% per year).
High Growth Earnings: REGN's earnings are forecast to grow, but not significantly.
Revenue vs Market: REGN's revenue (6% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: REGN's revenue (6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: REGN's Return on Equity is forecast to be low in 3 years time (18.8%).
How has Regeneron Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: REGN has high quality earnings.
Growing Profit Margin: REGN's current net profit margins (42.3%) are higher than last year (32.2%).
Past Earnings Growth Analysis
Earnings Trend: REGN's earnings have grown significantly by 30.6% per year over the past 5 years.
Accelerating Growth: REGN's earnings growth over the past year (65.9%) exceeds its 5-year average (30.6% per year).
Earnings vs Industry: REGN earnings growth over the past year (65.9%) exceeded the Biotechs industry -7.3%.
Return on Equity
High ROE: REGN's Return on Equity (31.9%) is considered high.
How is Regeneron Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: REGN's short term assets ($9.8B) exceed its short term liabilities ($2.7B).
Long Term Liabilities: REGN's short term assets ($9.8B) exceed its long term liabilities ($3.4B).
Debt to Equity History and Analysis
Debt Level: REGN's debt to equity ratio (17.9%) is considered satisfactory.
Reducing Debt: REGN's debt to equity ratio has increased from 0.3% to 17.9% over the past 5 years.
Debt Coverage: REGN's debt is well covered by operating cash flow (132.3%).
Interest Coverage: REGN's interest payments on its debt are well covered by EBIT (57.9x coverage).
What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of REGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Leonard Schleifer (67 yo)
Dr. Leonard S. Schleifer, M.D., Ph.D., founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron P...
CEO Compensation Analysis
Compensation vs Market: Leonard's total compensation ($USD21.46M) is above average for companies of similar size in the US market ($USD10.94M).
Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.
Experienced Management: REGN's management team is considered experienced (2 years average tenure).
Experienced Board: REGN's board of directors are seasoned and experienced ( 19.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Regeneron Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Regeneron Pharmaceuticals, Inc.
- Ticker: REGN
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$49.486b
- Shares outstanding: 104.14m
- Website: https://www.regeneron.com
Number of Employees
- Regeneron Pharmaceuticals, Inc.
- 777 Old Saw Mill River Road
- New York
- United States
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/10 22:11|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.